telithromycin - Profile

What are the generic drug sources for telithromycin and what is the scope of patent protection?

Telithromycin is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for telithromycin

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for telithromycin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-002	Feb 9, 2005		DISCN	No	No
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-001	Apr 1, 2004		DISCN	No	No

Expired US Patents for telithromycin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-002	Feb 9, 2005
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-001	Apr 1, 2004
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-002	Feb 9, 2005
Sanofi Aventis Us	KETEK	telithromycin	TABLET;ORAL	021144-001	Apr 1, 2004

EU/EMA Drug Approvals for telithromycin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Aventis Pharma S.A.	Ketek	telithromycin	EMEA/H/C/000354When prescribing Ketek, consideration should be given to official guidance on the appropriate use ofantibacterial agents and the local prevalence of resistance.Ketek is indicated for the treatment of the following infections:In patients of 18 years and oldercommunity-acquired pneumonia, mild or moderate.when treating infections caused by known or suspected beta-lactam- and / or macrolide-resistant strains (according to history of patients or national and / or regional resistance data) covered by the antibacterial spectrum of telithromycin:acute exacerbation of chronic bronchitis;acute sinusitis;In patients of 12 years and oldertonsillitis / pharyngitis caused by Streptococcus pyogenes, as an alternative when beta-lactam antibiotics are not appropriate in countries / regions with a significant prevalence of macrolide-resistant S. pyogenes, when mediated by ermTR or mefA.	Withdrawn	no	no	no	2001-07-09
Aventis Pharma S.A.	Levviax	telithromycin	EMEA/H/C/000355When prescribing Levviax consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1).Levviax is indicated for the treatment of the following infections:In patients of 18 years and older:-Community-acquired pneumonia, mild or moderate (see section 4.4).- When treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1):- Acute exacerbation of chronic bronchitis,- Acute sinusitisIn patients of 12 years and older:- Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1).	Withdrawn	no	no	no	2001-07-09

Telithromycin Investment Scenario and Fundamentals Analysis

Last updated: February 27, 2026

What is Telithromycin?

Telithromycin is a ketolide antibiotic, approved in 2004 for community-acquired pneumonia (CAP). It was developed by Sanofi-Aventis and marketed under the brand name Ketek. Its mechanism targets bacterial protein synthesis, offering broad-spectrum activity against respiratory pathogens.

Market Overview and Competitive Position

Aspect	Details
Approved Indication	Community-acquired pneumonia (CAP)
Current Market Status	Withdrawn from several markets due to safety concerns
Key Competitors	Amoxicillin, Macrolides (azithromycin, clarithromycin), Fluoroquinolones
Peak Sales (2004–2010)	Estimated $300 million globally, before safety issues arose

Regulatory and Safety Considerations

Issue	Impact
Black Box Warning	Liver toxicity, including fatalities
Market Withdrawal	US (2006), several European countries (2006–2008)
Post-Marketing Risks	Limited untapped markets, ongoing safety monitoring

Fundamentals Analysis

Revenue and Market Potential

Initially projected to reach $500–$700 million globally (by 2010), actual revenues declined sharply due to safety concerns. Presently, the drug is withdrawn from major markets, significantly reducing its commercial viability.

Patent and Lifecycle Status

| Patent Status | Expired or nearing expiry (2009–2015) | | Generic Competition | Limited, due to safety controversies maintaining market barriers in some regions | | Regulatory Exclusivity | Previously granted, but revoked following safety issues |

Development and Regulatory Trends

The safety profile has limited new development, with no recent approvals. Ongoing research into safety mitigations or alternative formulations remains scarce, constraining new investment.

Industry and Investor Sentiment

Investors regard telithromycin as a high-risk asset. Investment interest diminishes where safety concerns override commercial gains. Companies focus on new antibiotics with better safety profiles and less regulatory risk.

Future Outlook and Risks

Factors	Risks and Opportunities
Clinical Development	Limited, as safety issues restrict further trials
Regulatory Environment	Increasing safety monitoring, stricter approvals
Market Freshness	Minimal incoming revenue streams due to market withdrawal
Resistance Development	Few data points, but potential resistance issues could affect related drugs

Summary

Telithromycin's initial promise was undermined by safety issues, leading to market withdrawal and minimal future market potential. Investments are constrained by regulatory risk, safety liabilities, and static pipeline prospects.

Key Takeaways

• Telithromycin's market has largely disappeared due to safety concerns, primarily hepatotoxicity.
• Revenue potential is near zero in most markets, with limited prospects for recovery.
• Patent expiration and safety issues diminish attractiveness for R&D investments.
• Regulatory scrutiny intensifies, increasing the risk profile for future development.
• Investment risk remains high; potential value is limited to legacy markets or niche applications with safety assurances.

FAQs

1. Is there ongoing research to revive telithromycin?
Limited. Most research focuses on developing safer ketolide derivatives or alternative antibiotics, rather than reviving telithromycin itself.

2. Can telithromycin be repurposed for other infections?
No. Its safety profile restricts its use, and no significant efforts exist for repurposing, given the associated risks.

3. What are the main regulatory hurdles?
Safety concerns, particularly hepatotoxicity, lead to strict post-marketing surveillance and withdrawal in multiple markets.

4. Does patent expiry impact the potential for generic sales?
Patent expiry has not translated into commercial opportunities due to safety concerns, which impede generic approval.

5. Are there alternatives to telithromycin with similar efficacy and safety?
Yes. Macrolides like azithromycin and clarithromycin offer comparable efficacy with better safety profiles.

References

1. [1] DrugBank. Telithromycin. Retrieved from https://go.drugbank.com/drugs/DB00786
2. [2] U.S. Food and Drug Administration (FDA). Ketek (telithromycin) information. 2006.
3. [3] European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC) recommendation on Ketek. 2008.
4. [4] Anon. (2004). "Market analysis of ketolide antibiotics". International Journal of Antimicrobial Agents.
5. [5] FDA. (2006). "Warnings and Precautions for Ketek". Federal Register.